Drik-Preclinical CRO is a contract research laboratory focusing on affordable, quality-driven services in the biotechnology and healthcare industries. Founded in 2012 and headquartered in the United States, Drik offers customized toxicology studies to support clients' discovery processes. The company's value-added services, such as prefigure toxicity screening, aim to facilitate better decision-making earlier in the discovery phase.
In August 2013, Drik secured a $500.00K Series A investment from Stillwater National Bank and i2E. This injection of capital signifies the confidence of these investors in Drik's approach and potential within the preclinical CRO market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $500.00K | 2 |
|
12 Aug 2013 |
No recent news or press coverage available for Drik-Preclinical CRO.
We care about your data, and we'd love to use cookies make your experience better.
